Weight-loss drugs can improve kidney health, study finds. is true? are the finding convincing
Recent studies have indeed found compelling evidence that weight-loss drugs, particularly GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy), can improve kidney health. The findings are convincing for several reasons:
Comprehensive Clinical Trials
A meta-analysis of 11 large-scale clinical trials involving 85,373 participants provided robust evidence of the kidney-protective effects of GLP-1 receptor agonists[2]. This extensive dataset lends significant credibility to the findings.
Specific Kidney Health Improvements
The studies demonstrated several key benefits for kidney health:
- 16% reduction in the risk of kidney failure[2][4]
- 22% reduction in the risk of worsening kidney function[2][4]
- 19% combined reduction in the risk of kidney failure, worsening kidney function, and death due to kidney disease[2]
Benefits Beyond Diabetes
Importantly, these kidney health improvements were observed in people both with and without diabetes[2][3]. This suggests that the benefits extend beyond diabetes management and may be applicable to a broader population.
Mechanism of Action
The kidney-protective effects of GLP-1 receptor agonists are likely due to a combination of factors:
- Weight loss, which reduces stress on organs, including the kidneys[1]
- Improved blood sugar control
- Reduced inflammation associated with obesity[1]
Additional Cardiovascular Benefits
The studies also confirmed cardiovascular benefits, including:
- 14% reduction in the risk of cardiovascular death, non-fatal heart attack, and non-fatal stroke[2]
- 13% lower risk of death from any cause[2][4]
These cardiovascular improvements are particularly relevant for kidney health, as cardiovascular disease is a major risk factor for kidney problems.
Expert Opinions
Leading researchers and medical professionals have expressed confidence in these findings:
- Prof. Helen M. Colhoun from the University of Edinburgh stated that semaglutide “may contribute to a significant reduction in the risk of kidney-related complications”[1]
- Dr. Sunil Badve, lead author of a major study, emphasized the clear benefit of GLP-1 receptor agonists on kidney failure and end-stage kidney disease[2]
While these findings are convincing, it’s worth noting that some researchers suggest further investigation is needed to determine if the kidney function improvement is independent of weight loss[1]. Additionally, a comparison study found that bariatric surgery may be even more effective than GLP-1 drugs for preserving kidney function in people with obesity and type 2 diabetes[5].
In conclusion, the evidence strongly supports the claim that weight-loss drugs, particularly GLP-1 receptor agonists, can improve kidney health. The findings are based on large-scale, well-designed studies and are corroborated by multiple research teams, making them highly convincing.
Citations:
[1] Semaglutide use tied to lower kidney disease risk in obesity https://www.medicalnewstoday.com/articles/drugs-like-ozempic-could-protect-kidney-health-in-people-with-heart-disease-obesity
[2] Popular diabetes and obesity drugs also protect kidneys, study shows https://medicalxpress.com/news/2024-11-popular-diabetes-obesity-drugs-kidneys.html
[3] Weight loss drugs could help fight chronic kidney disease, study finds https://www.euronews.com/health/2024/11/26/weight-loss-drugs-could-help-fight-chronic-kidney-disease-study-finds
[4] Study Finds GLP-1 Meds Can Also Help the Kidneys https://www.usnews.com/news/health-news/articles/2024-11-26/study-finds-glp-1-meds-can-also-help-the-kidneys
[5] Obesity: Bariatric surgery better than GLP-1 drugs for kidney health https://www.medicalnewstoday.com/articles/weight-loss-surgery-may-preserve-kidney-health-more-effectively-than-glp-1-drugs
